RSV vaccine: Moderna, Pfizer start a new FDA approval race

January 18, 2023

The Covid vaccine is here to stay after a development process that broke the record books at both Moderna and Pfizer, but a new golden age ofvaccines may only be at its beginning.

Both companies have released results from RSV vaccine trials with efficacy results strong enough to expect expedited approval from the FDA. The latest was Moderna, which on Tuesday night share results from its RSV vaccine trial of over 37,000 individuals in 22 countries, effective at preventing lower respiratory tract disease.

Pfizer, whose RSV vaccine is focused on pregnant women able to transfer the antibodies to the fetus and offer protection for the first six months of life, previously released efficacy results of approximately 82% for the first 90 days of a child’s life.

Read more at CNBC.

Immunize Colorado